NeuroSigma, Inc. news
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate to severe ADHD at UCLA and Seattle Children’s Hospital for a blinded period of 4 weeks
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to commence the largest trial of external Trigeminal Nerve Stimulation (eTNS) ever conducted.
NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its
NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced today that Ignis Therapeutics has acquired the exclusive license in China (including Hong Kong and Macau) of NeuroSigma’s
NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer of the Monarch eTNS System<
NeuroSigma, Inc., a bioelectronic medical device company, announced today that KT Corporation has made a $5 million equity investment in NeuroSigma. NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive external trigeminal nerve stimulation (eTNS) to treat
KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy. NeuroSigma is the developer of the
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to tr
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for t